Pillot T, Barbier A, Visvikis A, Lozac'h K, Rosseneu M, Vandekerckhove J, Siest G
Centre du Médicament, URA CNRS 597, Nancy, France.
Protein Expr Purif. 1996 Jun;7(4):407-14. doi: 10.1006/prep.1996.0061.
We have cloned, from total human liver RNA, the cDNA encoding apolipoprotein E3 (apoE3). Site-directed mutagenesis was used to obtain the cDNA encoding the apoE4 isoform, a major variant of this apolipoprotein in man. These two cDNAs were subcloned into the procaryotic expression vector pAHRS. A polyhistidine tag was added at the NH2-termini of the recombinant proteins (apoE3 and apoE4) to enable rapid purification. The resulting plasmids (pAHRS-apoE3 and pAHRS-apoE4) were introduced into the Escherichia coli strain BL21(DE3). Recombinant strains were grown at 37 degrees C in a Luria and Bertani medium and the addition of isopropyl beta-thiogalactoside resulted in the expression of large amounts of apoE protein (40.5 kDa), representing at least 15% of cellular proteins. The recombinant apoE isoforms were purified, under denaturating conditions, in one step by affinity chromatography on a Ni-chelated agarose column, yielding to about 20 mg of 96% pure protein per liter of culture. Compared to plasma apoE3 purified from human very low density lipoproteins, the two renatured recombinant apoE isoforms have the same secondary structure content, as revealed by circular dichroism measurement. Moreover, the recombinant apoE3 isoform shares similar properties for the association with lipids, compared to the human protein, indicating that the addition of the amino-terminal polyhistidine peptide does not influence the structure and the lipid binding properties of this recombinant apoE isoform. No differences in the secondary structure of recombinant apoE4 were detected, whereas this isoform presents specific reactivity with lipids. This simple and rapid procedure for the expression and the purification of functional recombinant apoE should therefore enable structural and physiological studies requiring large amounts of these apolipoproteins.
我们从人肝脏总RNA中克隆出编码载脂蛋白E3(apoE3)的cDNA。采用定点诱变技术获得了编码apoE4异构体的cDNA,apoE4是该载脂蛋白在人体内的一种主要变体。将这两个cDNA亚克隆到原核表达载体pAHRS中。在重组蛋白(apoE3和apoE4)的氨基末端添加了一个多组氨酸标签,以便快速纯化。将所得质粒(pAHRS-apoE3和pAHRS-apoE4)导入大肠杆菌菌株BL21(DE3)。重组菌株在37℃的Luria和Bertani培养基中生长,添加异丙基β-硫代半乳糖苷后可表达大量的apoE蛋白(40.5 kDa),其含量至少占细胞蛋白的15%。在变性条件下,通过镍螯合琼脂糖柱上的亲和层析一步纯化重组apoE异构体,每升培养物可产生约20 mg纯度为96%的蛋白。圆二色性测量结果显示,与从人极低密度脂蛋白中纯化的血浆apoE3相比,两种复性的重组apoE异构体具有相同的二级结构含量。此外,与天然蛋白相比,重组apoE3异构体在与脂质结合方面具有相似的特性,这表明氨基末端多组氨酸肽的添加不会影响该重组apoE异构体的结构和脂质结合特性。未检测到重组apoE4二级结构的差异,而该异构体与脂质具有特异性反应。因此,这种简单快速的功能性重组apoE表达和纯化方法应该能够满足需要大量这些载脂蛋白的结构和生理学研究。